Cornerstone Therapeutics Completes Acquisition of EKR Therapeutics

Cornerstone Therapeutics Inc. announced the closing of its acquisition of EKR Therapeutics, Inc., a privately-held specialty pharmaceutical company focused on the acute-care hospital setting. Pursuant to the merger agreement, EKR Therapeutics became a wholly owned subsidiary of Cornerstone. The merger was effective June 26, 2012.

If you have any questions about the merger, please contact Josh Franklin at (919) 678-6520.

 

© 2014 Cornerstone Therapeutics Inc. All rights reserved. G-Q112-01 Rev 7
About Us | Products | Business Development | Investors | Privacy Policy | Terms of Use | Sitemap